EUROIMMUN, a PerkinElmer company, has launched two CE-marked assays – the Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG). Both facilitate the detection of IgG antibodies formed against SARS-CoV-2.
Research shows that immune responses to SARS-Cov-2 infection, which are often measured by neutralising antibody titres, can vary greatly. Understanding how antibody levels decrease over time in certain individuals and populations could help answer critical epidemiological, clinical and virological questions, including those that lead to limiting virus transmission and further developing COVID-19 vaccines and therapeutics.
The Anti-SARS-CoV-2 RBD ChLIA (IgG) enables the quantitative measurement of IgG antibodies formed against the receptor binding domain (RBD) of SARS-CoV-2. In doing so, it offers the possibility to convert the determined antibody concentration into standardised units (BAU/mL). This assay is suitable for the determination of IgG antibody responses after infection or vaccination with a spike protein-based vaccine. EUROIMMUN also offers the IDS-i10 and IDS-iSYS Multi-Discipline Automated System that allows for automated processing of chemiluminescence immunoassays.
Similarly, the Anti-SARS-CoV-2 Omicron ELISA (IgG) complements EUROMMUN's portfolio of SARS-CoV-2 offerings. With Omicron remaining the dominant SARS-CoV-2 variant in many countries worldwide, this assay is based on the recombinant S1 subunit of the spike protein of the SARS-CoV-2 Omicron variant and can be used to quantify IgG antibodies formed against the virus.
The EUROIMMUN COVID-19 diagnostics portfolio also includes two real-time PCR tests, an antigen ELISA for acute diagnostics, as well as several serological tests for differentiated detection of antibodies (IgA, IgM, IgG) against SARS-CoV-2 antigens. Furthermore, EUROIMMUN offers an Interferon-gamma Release Assay (IGRA) to determine the activity of SARS-CoV-2-reactive T cells.
